We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
Updated safety advice has been issued to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on dutasteride.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
As football fans across the country get behind England, the MHRA wants to keep any Yellow Cards off the pitch – and instead let people know that Yellow Cards can make an important impact in a very different way by...
Product Safety Report for Shenzhen Opolo tech Co., Ltd Hair Dryer IN11-B001 presenting a risk of fire.
Topical hormone products such as gels and creams can be absorbed accidentally by pets through close contact.
The MHRA has reviewed the evidence for finasteride and dutasteride and the risk of suicidal thoughts and behaviours and has recommended further measures to minimise this risk.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).